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JPML PROCESS: A DEFENDANT’S PERSPECTIVE
Sheila L. Birnbaum, Hayden A. Coleman, Jacqueline D. Harrington and Ashley
A. Flynn*
INTRODUCTION
“Agreement is made more precious by disagreement.” While this quote,
attributed to Publius Syrus (fl. 85-43 B.C.), a Latin writer best known for his
proverbs, certainly was not written about modern-day litigators, it could have been.
Plaintiffs and defendants tend to (respectfully) disagree on most issues large and
small, and yet centralization of many cases through an MDL is one area where the
parties may find common ground—under the right circumstances. Defendants tend
to support MDLs when many cases are anticipated, and the benefits of streamlined
discovery and uniform rulings loom large. Nonetheless, coordination before an
MDL sometimes does not have the intended effect of increasing efficiency, for
example, when an MDL covers vastly different defendants and alleged injuries. In
those circumstances, defendants may find themselves disagreeing with plaintiffs
who seek centralization before the Judicial Panel on Multidistrict Litigation
(JPML, or “the Panel”) or trying to carve out categories of cases to avoid being
swept into an overbroad MDL. To be successful, defendants must recognize that
the Panel itself is a singular institution where defendants must carefully coordinate
and pick their battles. Even then, making successful arguments concerning the
MDL location or judge may prove challenging.
This article focuses on four key questions from the defense perspective
concerning the formation of MDLs. One, what factors should defendants consider
when faced with an MDL? Two, how can defendants avoid being swept into an
MDL when they have determined that it is not in their interests? Three, what are
the prospects for defendants to argue successfully in favor of a particular MDL
location? Four, what types of arguments should defendants focus on before the
Panel? While these are not the only considerations relevant to defendants, we hope
that they will provide a flavor for the types of issues defendants typically consider
during the initial stages of MDL formation.

*
Sheila L. Birnbaum is co-chair of Dechert LLP’s product liability and mass torts practice. She is
one of the country’s preeminent product liability defense lawyers. Hayden A. Coleman is a partner
in Dechert’s product liability and mass torts group, focusing on representing pharmaceutical,
consumer goods and insurance companies facing all forms of aggregate litigation. Jacqueline D.
Harrington and Ashley A. Flynn are associates in Dechert’s product liability and mass torts group.
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I. WHAT FACTORS SHOULD DEFENDANTS CONSIDER WHEN
FACED WITH AN MDL? COPYCATS VS. EFFICIENCY
Defendants have a lot to consider in deciding whether to advocate for
centralization, oppose centralization, or take no position on the issue. While MDLs
can encourage the filing of additional lawsuits of dubious merit, they can also be a
critical tool to help defendants manage costs, streamline discovery, and understand
the value of a case for settlement purposes.
A. The Field of Dreams
We’ll leave our friends from the plaintiffs’ bar to explain the
circumstances under which they prefer MDLs, but from a defense perspective, the
reasons not to prefer an MDL are clear. Defendants know that once an MDL is
formed, plaintiffs who might not otherwise file a claim will appear from around
the country to join. Some commentators have observed that MDLs invite meritless
claims because (1) lawyers anticipate that there “will be a settlement in the MDL
transferee court in which they can get ‘inventory value’ for their claims” before
remand to the original court and (2) “amassing a large inventory of claims can
support a lawyer’s quest for appointment to a leadership position in the MDL.”1
For this reason, MDLs are often analogized to the Field of Dreams: “If you build
it, they will come.”2 Additionally, any adverse rulings or jury verdicts can be
exacerbated when numerous cases are consolidated in an MDL.
Though the creation of an MDL may trigger additional filings, mere
representations by counsel that more actions will be filed does not appear to
strongly influence the Panel. In 2012, the Panel considered centralization of claims
arising out of alleged defects in the da Vinci Robotic Surgical System. The Panel
noted that “[w]hile proponents maintain that this litigation may encompass
‘hundreds’ of cases or ‘over a thousand’ cases, we are presented with, at most, five
actions.”3 The Panel has also recognized that the number of cases may not always
be a relevant consideration when the cases are pending in relatively few districts.
This is particularly true where the cases are in the same district and/or assigned to
the same judge. For example, centralization has been denied where six actions
were pending in just two districts, with five of the actions in the same district and
assigned to the same judge.4 The Panel concluded “centralization [was] not
Advisory Committee on Civil Rules, Agenda Book, Nov. 1, 2018, p. 143, available at
https://www.uscourts.gov/sites/default/files/2018-11_civil_rules_agenda_book_0.pdf.
2
See, e.g., id.; James M. Beck, Stray Thoughts from the ACI Conference, Drug & Device Law (Dec.
17,
2007),
https://www.druganddevicelawblog.com/2007/12/stray-thoughts-from-aciconference.html.
3
In re Intuitive Surgical, Inc., Da Vinci Robotic Surgical Sys. Prods. Liab. Litig., 883 F. Supp. 2d
1339, 1340 (J.P.M.L. 2012).
4
See In re SLB Enter. RICO Litig., MDL No. 2899, Order Denying Transfer at 1-2 (J.P.M.L. July
31, 2019).
1
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necessary for the convenience of the parties and witnesses or to further the just and
efficient conduct of the litigation” as there were “only two sets of pretrial
proceedings to coordinate.”5
Where only a small number of actions are at issue, the Panel has reminded
practitioners that “the proponent of centralization bears a heavier burden to
demonstrate that centralization is appropriate.”6 The Panel has routinely denied
MDL applications where litigation involved just a small number of individual
claims.7 This tendency to deny centralization generally has been the case even
when defendants try to use the Field of Dreams argument as a sword in support of
centralization. In the TrueCar litigation, for example, defendants sought to
centralize just two actions pending in two different jurisdictions, where the
plaintiffs alleged the defendants breached their fiduciary duties (or aided and
abetted such breaches) to TrueCar by causing the company to issue false and
misleading statements.8 At oral argument, the defendants argued “several other
cases were likely to be filed.”9 The Panel rejected this argument, holding that it
was “reluctant to grant [MDL] centralization based on the mere possibility of
future actions.”10
B. A “Precious” Moment of Agreement
If MDLs can beget more and more lawsuits, why would defendants ever
want an MDL? For both parties, the objectives of forming an MDL are all rooted
in efficiency: (1) streamline the discovery process to “eliminate duplicative
discovery”; (2) “prevent inconsistent pretrial rulings”; and (3) conserve the
resources of both the parties and the courts.11 Thus, in the appropriate
circumstances, both parties may find “precious” agreement that an MDL is
desirable.
For example, in litigation involving thirty-two actions relating to the use
of the oral contraceptives called Yaz or Yasmin, both sides (largely) supported
centralization. The Panel agreed, finding the cases “involve[d] common questions
Id.
In re Bernzomatic and Worthington Branded Handheld Torch Prods. Liab. Litig., MDL No. 2897,
Transfer Order at 1 (J.P.M.L. July 31, 2019) (three actions in three judicial districts).
7
See, e.g., In re Intuitive Surgical, Inc., Da Vinci Robotic Surgical Sys. Prods. Liab. Litig., 883 F.
Supp. 2d at 1340 (denying centralization of five personal injury and wrongful death actions involving
alleged defects in a surgical device); In re Abbott Labs., Inc., Similac Prods. Liab. Litig., 763 F.
Supp. 2d 1376, 1376-77 (J.P.M.L. 2011) (denying centralization of nine actions alleging injury from
recalled baby formula).
8
See In re TrueCar, Inc., Shareholder Derivative Litig., MDL No. 2900, Order Denying Transfer
Order at 1-2 (J.P.M.L. July 3, 2019).
9
Id.
10
Id. (citing In re Intuitive Surgical, Inc., Da Vinci Robotic Surgical Sys. Prods. Liab. Litig., 883 F.
Supp. 2d at 1340 (“While proponents maintain that this litigation may encompass ‘hundreds’ of cases
or ‘over a thousand’ cases, we are presented with, at most, five actions.”)).
11
See, e.g., In re Hyundai & Kia Fuel Econ. Litig., 923 F. Supp. 2d 1364, 1365 (J.P.M.L. 2013); In
re Ford Fusion & C-Max Fuel Econ. Litig., 949 F. Supp. 2d 1368, 1369 (J.P.M.L. 2013); In re Land
Rover LR3 Tire Wear Prods. Liab. Litig., 598 F. Supp. 2d 1384, 1385 (J.P.M.L. 2009).
5
6
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of fact, and that centralization . . . will serve the convenience of the parties and
witnesses and promote the just and efficient conduct of this litigation.”12 Similarly,
in litigation related to whether Zoloft had caused birth defects in utero, Pfizer
sought to consolidate fifty-nine pending actions in an MDL.13 The briefing focused
on arguments that an MDL would streamline discovery and avoid inconsistent
pretrial rulings.14 In both of these examples, the fight between the parties focused
on where the Panel should send the MDL, not whether an MDL should form.
Parties are most likely to agree that an MDL is advantageous when
multiple cases have already been filed or will be filed regardless of whether an
MDL exists, and defendants find value in limiting the number of venues in which
they will have to defend themselves. For example, 3M recently supported
centralization of the more than 200 Combat Arms Earplug actions filed against it;
the allegations were that defective earplug design prevented a snug fit in the
wearer’s ear, leading to hearing loss or tinnitus.15 At that time, plaintiffs’ counsel
had signaled their intent to file “thousands” more actions.16 As with the oral
contraceptive and Zoloft litigations, the focus of the argument was on the location
of an MDL as the parties were unanimous in their view that an MDL should form.
II. HOW CAN DEFENDANTS AVOID GETTING SWEPT INTO AN
MDL WHEN THEY HAVE DETERMINED IT IS NOT IN THEIR BEST
INTERESTS? DIFFERENTIATION IS KEY
Although the objectives of forming an MDL are rooted in efficiency, there
are situations in which centralization may not achieve this goal. Defendants
advocate against formation or oppose the transfer of particular actions into an
MDL where there are, in our view, too many types of defendants, too many types
of injuries, or both.
When arguing against centralization, defendants should focus not only on
whether “common” factual issues exist, but also whether such issues are complex
and burdensome enough to warrant an MDL. For example, all defendants opposed
centralization sought by plaintiffs in litigation alleging injuries caused by spray
polyurethane foam (“SPF”) insulation products installed in plaintiffs’ properties.17
The Panel concluded that far from making the case more efficient, “placing direct
competitor manufacturer defendants into the same litigation would require
protecting trade secret and confidential information from disclosure to all parties
In re Yasmin & Yaz Mktg., 655 F. Supp. 2d 1343, 1343 (J.P.M.L. 2009).
Brief in Support of Defendant Pfizer Inc.’s Motion Pursuant to 28 U.S.C § 1407 to Transfer Related
Actions for Coordinated Pretrial Proc. in the S. Dist. of N.Y. at 1, In re Zoloft (Sertanline
Hydrochloride) Prods. Liab. Litig., 856 F. Supp. 2d 1347 (J.P.M.L. 2012) (MDL No. 2342).
14
Id. at 7-8.
15
Defendant 3M Co.’s Response to Motion to Transfer Related Actions for Coordinated Pretrial
Proceedings at 3, In re 3M Combat Arms Earplug Prods. Liab. Litig., 366 F. Supp. 3d 1368 (J.P.M.L.
2019) (MDL No. 2885).
16
Id. at 1.
17
In re Spray Polyurethane Foam Insulation Prods. Liab. Litig., 959 F. Supp. 2d. 1364, 1364
(J.P.M.L. 2013).
12
13
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and complicate case management.”18 And while there were certain overlapping
questions, “individualized facts concerning the chemical composition of the
different products, the training and practices of each installer, and the
circumstances of installation at each residence will predominate over the common
factual issues alleged by plaintiffs.”19
Similarly, in August 2020, the Panel declined to centralize hundreds of
cases filed by businesses seeking insurance coverage for losses during the COVID19 pandemic. The Panel concluded “the MDL that movants request entails very
few common questions of fact, which are outweighed by the substantial
convenience and efficiency challenges posed by managing a litigation involving
the entire insurance industry.”20 However, the Panel indicated it might be open to
the creation of smaller, “single-insurer” MDLs which “are more likely to involve
insurance policies utilizing the same language, endorsements, and exclusions,” and
“thus would not entail the managerial problems of an industry-wide MDL
involving more than a hundred insurers.”21 The Panel directed these “singleinsurers” to submit briefing on an expedited basis to show cause for why those
actions should not be centralized, noting “that delay should be avoided in this
litigation to the extent possible.”22
In subsequent hearings, the Panel examined proposed MDLs with respect
to six particular groups of insurers, concluding that centralization was not
appropriate as to four insurers because it would further complicate the litigation.23
For example, in one of the denials, the Panel considered whether to centralize
sixty-six actions brought against a single group of insurers.24 The Panel found that
centralization was a “close question” given that the insurance policies “appear to
use standard forms and will involve the interpretation of common policy
language.”25 But weighing against centralization, the Panel noted that “time is of
the essence in this litigation” given that “[m]any plaintiffs are on the brink of
bankruptcy as a result of business lost due to the COVID-19 pandemic and the
government closure orders.”26 Under these circumstances, the Panel concluded
that efficiency was “best obtained outside the MDL context.”27 In contrast, the
Panel concluded that centralization was appropriate against two other insurers

Id.
Id.
20
In re COVID-19 Bus. Interruption Prot. Ins. Litig., 2020 U.S. Dist. LEXIS 144446, at *5 (J.P.M.L.
Aug. 12, 2020) (MDL No. 2942).
21
Id. at *6.
22
Id.
23
In re Erie COVID-19 Bus. Interruption Prot. Ins. Litig., 2020 WL 7384529, at *1 (J.P.M.L. Dec.
15, 2020) (MDL No. 2969).
24
In re Hartford COVID-19 Bus. Interruption Prot. Ins. Litig., 2020 WL 5884782, at *1 (J.P.M.L.
Oct. 2, 2020) (MDL No. 2963).
25
Id. at *2.
26
Id.
27
Id.
18
19
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where the actions were likely to be more limited in geographic scope and therefore
more “manageable.”28
Likewise, in the recent case of the aqueous-film forming foams (“AFFF”)
litigation, some defendants successfully argued against transfer of three cases into
an MDL by citing to the many factual differences between the cases in which they
were named, and the other cases proposed for consolidation.29 The AFFF cases
involved the discharge of firefighting foam for training purposes by the military
and other users at military bases, airports, fire training centers, and other locations.
In contrast, three other cases involved the alleged presence of Perfluorooctanoic
acid (“PFOA”) in groundwater and municipal water, but these were not alleged to
be based on claims involving AFFF or the users of AFFF. 30 Defendants in these
PFOA cases successfully argued that adding these cases to the AFFF MDL would
“disrupt rather than promote efficiency.”31 And the MDL panel found that it would
be “devoted to scores of cases that involve particularized facts and claims wholly
distinct” from the facts and claims in the three PFOA cases.32 The Panel agreed
that the actions did not belong in the MDL, noting that the cases were “different in
kind from the AFFF actions and involve more varied defendants,” and were “being
managed effectively in their current districts.”33 In particular, the Panel
acknowledged that the inclusion of such cases in the MDL would undermine the
goal of efficiency and “could quickly become unwieldy.”34
On the other hand, in considering whether to form an MDL to address
alleged improper marketing and distribution of various prescription opiate
medications, the Panel rejected carve out arguments made by certain plaintiffs and
defendants to avoid centralization of specific cases.35 Defendants focused on the
fact that they were named in a limited number of cases with distinct allegations, or
argued the claims against them were distinct because, for example, they involved
captive wholesale distributors of opioids. Even though individualized factual

In re Erie COVID-19 Bus. Interruption Prot. Ins. Litig., 2020 WL 7384529, at *2.
In re Aqueous Film-Forming Foams Prods. Liab. Litig., 357 F. Supp. 3d 1391, 1392 (J.P.M.L. Oct.
19, 2018) (MDL No. 2873).
30
Id.
31
Brief in Response of Saint-Gobain Performance Plastics Corp. and Honeywell International Inc.
In Opposition to 3M’s Motion to Transfer Actions Pursuant to 28 U.S.C. § 1407 at 2, In re Aqueous
Film-Forming Foams Prods. Liab. Litig., 357 F. Supp. 3d 1391, 1392 (J.P.M.L. 2018) (MDL No.
2873).
32
Id.
33
In re Aqueous Film-Forming Foams Prods. Liab. Litig., 357 F. Supp. 3d at 1396.
34
Id.
35
In re Nat’l Prescription Opiate Litig., MDL No. 2804, Transfer Order at 3 (J.P.M.L. 2017).
28
29
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issues might arise, the Panel concluded that they did not “negate the efficiencies
to be gained by centralization.”36
III. WHAT ARE THE PROSPECTS FOR DEFENDANTS TO ARGUE
SUCCESSFULLY IN FAVOR OF A PARTICULAR MDL LOCATION?
NO ONE KNOWS
As many practitioners have observed, one of the “least predictable aspects
of panel practice” is the selection of venue for a new MDL proceeding.37 The Panel
considers various factors in selecting the MDL district, including: the location of
parties’ headquarters (where witnesses and documents are likely located), districts
with the most cases or most procedurally advanced case(s), and the location of the
first-filed action.38 Typically, as found in a study cited in the Introduction to this
Symposium, the Panel “tends to follow the preferences of the parties when they
agree on where to consolidate the cases. When the parties disagree, the study found
that ‘the Panel sides with plaintiffs and defendants roughly equally.’”39
The Panel also considers the experience of the potential MDL judge, the
familiarity of the MDL judge with factual or legal issues at play, and the docket
conditions of a potential transferee district or MDL judge.40 In particularly large
and complex MDLs, the Panel may choose a judge with prior experience managing
an MDL.41 But lack of MDL experience does not preclude a judge from being
assigned to an MDL. In fact, the Panel has made a point to provide judges without
prior MDL experience the opportunity to supervise an MDL should they want it,
even in cases that might prove to have significant volume and complexity.42
Because of the many considerations that go into selection of an MDL
location, parties can sometimes be surprised by how venues and judges are chosen.
The Panel will often hear scores of arguments advocating for particular locations,
Id.
Alan Rothman, And Now a Word from The Panel: 5 MDL Lessons, LAW360 (Nov. 28, 2017),
https://www.law360.com/articles/988626/and-now-a-word-from-the-panel-5-mdl-lessons.
38
Id.; Alan Rothman, And Now a Word from the Panel: Spotlight on MDL Venue, LAW360 (Mar. 25,
2020), https://www.law360.com/articles/1256760/print?section=banking.
39
Ryan C. Hudson, Rex Sharp, & Nancy Levit, MDL Cartography: Mapping the Five Stages of a
Federal MDL, 89 UMKC L. REV. 801, 808 (2021) (quoting Zachary D. Clopton & Andrew D. Bradt,
Party Preferences in Multidistrict Litigation, 107 CAL. L. REV. 1713, 1714 (2019)).
40
Kristen K. Bromberek, MDL Strategies: Choosing a Transferee Court, ALSTON & BIRD (Jan. 9,
2015),
https://www.alston.com/en/insights/publications/2015/01/mdl-strategies-choosing-atransferee-court-ilaw360/.
41
In re Nat’l Prescription Opiate Litig., 290 F. Supp. 3d 1375, 1379, Transfer Order (J.P.M.L. Dec.
5, 2017) (MDL No. 2804) (assigning Judge Dan A. Polster noting he was an “experienced transferee
judge who presides over several opiate cases” with “previous MDL experience. . .which involved
several hundred cases, which has provided him valuable insight into the management of complex,
multidistrict litigation”).
42
See, e.g., In re Domestic Airline Travel Antitrust Litig., MDL No. 2656, Transfer Order at 2
(J.P.M.L. Oct. 13, 2015) (“[C]entralization in this district provides us the opportunity to assign the
litigation to the Honorable Colleen Kollar-Kotelly, an able and experienced jurist who has not yet
had the opportunity to preside over a multidistrict litigation.”).
36
37
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and then a seemingly unlikely venue without broad support of the parties will be
selected. Exacerbating the sense that these decisions are a bit of a black box, the
Panel has even assigned MDLs to districts not requested by any party, including
districts without any pending cases.43 In deciding to assign an MDL to a district
without any cases, the Panel may consider, for example, that “litigation is
nationwide in scope, and thus almost any district would be an appropriate forum”
and that the judge to whom the MDL is assigned has relevant experience that will
“facilitate the just and efficient conduct” of the litigation.44
IV. WHAT ARGUMENTS SHOULD DEFENDANTS FOCUS ON
BEFORE THE PANEL? COORDINATE AND PICK YOUR BATTLES
The Panel is always well prepared. If you are arguing in front of the Panel,
you can assume that the judges have read the parties’ briefs and have a list of
questions prepared. As mentioned in this Symposium’s Introduction, in contrast to
a traditional oral argument, it is not uncommon for parties to be limited to two to
three minutes at oral argument. Defendants should be guided by a few principles
to use their time wisely: (1) coordinate with co-defendants; (2) don’t fight on what
is not in dispute; (3) don’t rehash your brief; and (4) avoid sounding like a travel
agent.
Coordinate with co-defendants. Coordinate with co-defendants in
advance of the hearing, if possible, to use your time wisely. Indeed, the Panel
advises attorneys arguing the same viewpoint to designate a single representative.45
For example, at a recent hearing on whether to centralize hundreds of COVID-19
insurance cases, a single attorney argued on behalf of more than 30 insurers who
uniformly opposed the creation of an MDL.46 Coordinating with co-defendants in
advance of the hearing allows you to aggregate your time through a single
representative, maximizing the number of arguments your group will be able to
make.
Pick your battles. If all parties agree on an issue, do not waste what little
time you have before the Panel on a non-issue. In the 3M litigation discussed
above, where all parties unanimously supported an MDL, the entire argument
focused on what court was best suited to hear the cases.47 That being said, as

43
See, e.g., In re Pella Corp. Architect and Designed Series Windows Prods. Liab. Litig., 996 F.
Supp. 2d 1380, 1382 (J.P.M.L. Feb. 14, 2014) (MDL No. 2514) (noting “[a]lthough no constituent
action currently is pending in that district, that is no impediment to its selection as transferee
district”).
44
Id. at 1383.
45
Julie Zeveloff, 7 Tips for Maximizing Your Time Before the JPML, LAW360 (Sept. 21, 2010),
https://www.law360.com/articles/188341/print?section=classaction.
46
Jeff Sistrunk, 6 Key Moments from the COVID-19 Insurance MDL Hearing, LAW360 (July 31,
2020), https://www.law360.com/articles/1297345/print?section=classaction.
47
In re 3M Combat Arms Earplug Prods. Liab. Litig., 366 F. Supp. 3d 1368, 1369 (MDL No. 2885)
(J.P.M.L. Apr. 12, 2019).
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previously noted, it can be difficult to predict the venue or judge that the Panel will
select for the MDL.48
Don’t rehash your brief. As noted, the Panel will come to oral argument
thoroughly prepared and will have read your briefs, so make sure they are
comprehensive and persuasive; there is no need to rehash the arguments in your
brief. Your valuable time will best be spent updating the judges on any new
developments in the litigation, answering their questions, and driving home your
key points.
Avoid sounding like a travel guide. Although the Panel considers
convenience in its decision on where to transfer the MDL, it does not appear to be
their top priority. Instead, “[t]he arguments presented in favor of a particular
transferee district should be tied to the administrative factors that are likely to
influence the JPML’s decision.”49 Rather than focus on the merits of a location
(e.g., size of the local airport or number of nearby hotels), focus on the merits of
the district court and the evidentiary reasons why the case belongs there.
CONCLUSION
The formation of an MDL is one area where there may be “precious”
agreement in a litigation. Of course, any agreement at this stage of the litigation is
“precious” because it is rare, and often limited. Even when the parties agree on
centralization, agreement on location is usually elusive. And oftentimes, there is
no agreement on whether to form an MDL at all. Before the Panel, where time is
of the essence, defendants must be efficient, the hallmark goal of MDL formation
itself. And once the moment of agreement on MDL formation has passed (if it
occurred at all), it’s off to the races on the numerous disagreements that fuel
litigation.

48
49

See Rothman, supra note 37.
Bromberek, supra note 40.
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